1. Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma 
Julie M. Vose, Philip J. Bierman, Fausto R. Loberiza, Charles Enke, Jordan Hankins, Robert G. Bociek, Wing C. Chan, Dennis D. Weisenburger, James O. Armitage 
Biology of Blood and Marrow Transplantation 
Volume 19, Issue 1, Pages (January 2013)
DOI: /j.bbmt
Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Schema for 131-Iodine carmustine, etoposide, cytarabine, and melphalan (BEAM) transplantation program.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
(A) Progression-free survival for patients treated with 131-Iodine tositumomab/carmustine, etoposide, cytarabine, and melphalan (BEAM) and autologous stem cell transplantation (ASCT). (B) Overall survival for patients treated with 131-Iodine tositumomab/BEAM and ASCT.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
(A) Progression-free survival for patients who underwent transplantation in first partial response (N = 5), high-risk CR1 (N = 13), or relapsed diffuse large B cell lymphoma (DLBCL) (N = 22). (B) Overall survival for patients who underwent transplantation in first partial response (N = 5), high-risk CR1 (N = 13), and relapsed DLBCL (N = 22).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions